Equities
Health CareHealth Care Equipment & Services
  • Price (USD)96.91
  • Today's Change2.45 / 2.59%
  • Shares traded1.65m
  • 1 Year change8.90%
  • Beta0.7132
Data delayed at least 15 minutes, as of Apr 08 2020 16:52 BST.
More ▼

Profile data is unavailable for this security.

About the company

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

  • Revenue in USD (TTM)31.06bn
  • Net income in USD5.28bn
  • Incorporated2014
  • Employees90.07k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Digital Surgery LtdDeal completed13 Feb 202013 Feb 2020Deal completed-16.81%--
Stimgenics LLCDeal completed08 Jan 202008 Jan 2020Deal completed-15.36%--
Klue Labs IncDeal completed17 Dec 201917 Dec 2019Deal completed-15.39%--
Titan Spine IncDeal completed09 May 201909 May 2019Deal completed8.89%--
Data delayed at least 15 minutes, as of Apr 08 2020 16:52 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Edwards Lifesciences Corp4.35bn1.05bn40.37bn13.90k39.379.8235.459.294.954.9320.4919.840.73621.798.69312,805.8017.7715.1920.9318.1174.3774.3924.1421.992.60--0.12530.0016.7913.3642.245.2924.33--
Baxter International Inc11.36bn807.00m41.85bn50.00k53.585.3026.193.681.541.9221.9915.570.67013.956.08227,240.004.829.525.8711.9942.2242.297.1916.391.8116.600.403424.492.371.17-40.0012.04-18.18-16.14
Boston Scientific Corporation10.74bn4.70bn47.14bn36.00k10.133.398.254.393.333.337.619.950.41642.326.25298,194.4018.237.3722.689.3170.3770.7943.7816.230.64123.000.4190.009.287.78193.02--16.44--
Intuitive Surgical, Inc.4.48bn1.38bn57.21bn7.33k42.456.8835.8012.7711.5411.5437.4871.240.50952.726.75611,315.9015.7215.1417.6016.9269.4569.3030.8529.353.95--0.000.0020.2516.0122.2426.9232.15--
Stryker Corporation14.88bn2.08bn62.14bn40.00k30.244.8521.724.185.485.4839.1934.200.51861.635.70372,100.007.268.218.659.9765.8566.2313.9914.501.84--0.464136.529.439.004.4632.2422.7411.26
Becton Dickinson and Co17.35bn659.00m64.42bn70.09k99.183.0422.393.712.402.7763.4178.190.33093.438.09247,585.301.542.791.783.2247.7847.274.667.200.54685.180.477972.798.1815.4129.16-2.737.947.16
Thermo Fisher Scientific Inc.25.54bn3.70bn118.34bn75.00k32.293.9919.794.639.199.1763.3474.420.44574.465.62340,560.006.465.277.245.9444.3545.0314.5012.441.3810.310.37439.804.868.6221.2414.3416.714.28
Medtronic PLC31.06bn5.28bn126.59bn90.07k24.182.4415.884.083.913.9322.9838.640.34222.385.13344,861.305.854.396.494.9069.4669.2617.1114.552.2812.530.329954.462.0212.44-13.808.6623.4212.30
Abbott Laboratories31.90bn3.60bn144.48bn107.00k40.534.6421.844.532.022.0717.9117.640.47243.256.02298,168.205.333.966.274.6858.6457.2211.298.811.048.010.366980.964.349.5246.1415.918.757.30
Data as of Apr 08 2020. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD

Institutional shareholders

34.63%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2019112.34m8.38%
BlackRock Fund Advisorsas of 31 Dec 201970.45m5.26%
Wellington Management Co. LLPas of 31 Dec 201968.77m5.13%
SSgA Funds Management, Inc.as of 31 Dec 201957.86m4.32%
Massachusetts Financial Services Co.as of 31 Dec 201952.98m3.95%
Lazard Asset Management LLCas of 31 Dec 201928.71m2.14%
Geode Capital Management LLCas of 31 Dec 201919.69m1.47%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 201919.19m1.43%
Columbia Management Investment Advisers LLCas of 31 Dec 201917.30m1.29%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 201916.74m1.25%
More ▼
Data from 31 Dec 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.